

The prevalence of extramedullary acute myeloid leukemia detected by ¹⁸F-FDG-PET/CT: final results from the prospective PETAML trial

Friedrich Stölzel,¹ Tors Lür,¹ Steffen Löck,² Stefani Parmentier,³ Friederike Kuithan,⁴ Michael Kramer,¹ Nael S. Alakel,¹ Katja Sockel,¹ Franziska Taube,¹ Jan M. Middeke,¹ Johannes Schetelig,¹ Christoph Röllig,¹ Tobias Paulus,⁵ Jörg Kotzerke,⁶ Gerhard Ehninger,¹ Martin Bornhäuser,^{1,7,8} Markus Schaich^{3#} and Klaus Zoepfel^{6#}

¹Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Dresden, Germany; ²OncoRay - National Center for Radiation Research in Oncology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz Zentrum, Dresden Rossendorf, Germany; ³Department of Haematology and Oncology, Rems-Murr-Hospital, Winnenden, Germany; ⁴Department of Pathology, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Dresden, Germany; ⁵Department of Radiology, Städtisches Klinikum Dresden, Dresden, Germany; ⁶Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; ⁷National Center for Tumor Diseases NCT, Partner site Dresden, Dresden, Germany; ⁸Department of Haematological Medicine, The Rayne Institute, King's College London, London, UK

#MS and KZ contributed equally as co-senior authors.

©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2019.223032

Received: March 31, 2019.

Accepted: August 27, 2019.

Pre-published: August 29, 2019.

Correspondence: *FRIEDRICH STÖLZEL* - friedrich.stoelzel@uniklinikum-dresden.de

Supplementary Table S1. Patients with EM AML per ¹⁸F-DG-PET/CT and per histologically confirmed biopsy and patients with AML without EM AML as per ¹⁸F-DG-PET/CT.

PETAML n = 93*	EM and Histology positive / ¹⁸ F-DG-PET/CT positive n = 10	EM negative / ¹⁸ F-DG-PET/CT negative n = 72
Median age at diagnosis (range)	62 (43 to 77)	61.5 (27 to 76)
Gender, no. (percentage)		
Female	4 (40)	33 (46)
Male	6 (60)	39 (54)
Median percentage of bone marrow blasts at diagnosis (range)	77 (0.5 to 95)	46.0 (5.0 to 96.5)
Median WBC count at diagnosis, × 10 ⁹ /L (range)	7.73 (1.3 to 163)	6.1 (.4 to 187.8)
Median Serum LDH at diagnosis in mmol*s/l (range)	5.8 (2.7 to 25.5)	6.2 (2.4 to 36.5)
Median Serum C-reactive Protein at diagnosis in mg/L (range)	23.8 (2.6 to 369)	12.4 (0.9 to 297)
FAB subtypes at diagnosis no. (percentage)		
M0	2 (22)	2 (3)
M1	1 (11)	14 (20)
M2	3 (33)	28 (39)
M4	0	9 (13)
M5 a,b	2 (22)	8 (11)
M6	1 (11)	2 (3)
M7	0	3 (4)
RAEB-T	0	3 (4)
Cytogenetic subgroups, no. (percentage)		
Adverse risk AML	3 (30)	15 (22)
Intermediate risk AML	7 (70)	48 (72)
Favorable risk AML	0	4 (6)
Relapsed AML, no. (percentage)	4 (40)	5 (7)

AML type, no. (percentage)		
<i>de novo</i> AML	7 (70)	44 (61)
secondary AML (with preceding MDS)	1 (10)	18 (25)
tAML	2 (20)	10 (14)
Extramedullary manifestation in Follow-Up-PET/CT, no. (percentage)		
EM-AML positive	6 (60)	
EM-AML negative	4 (40)	

* The trial included a total of n = 93 AML patients. Nine patients could not be assigned to either group in this table because they were FDG-PET/CT positive for EM AML but did not undergo biopsy/histologic confirmation. Two patients could not be assigned to either group in this table because they were FDG-PET/CT positive for EM AML but on histologic diagnosis of the biopsies could not confirm EM AML but instead other tumors (see *Results*).

Supplementary Table S2. Patients undergoing biopsy for diagnosis of EM AML in both cohorts of the PETAML trial.

PETAML PATIENT COHORT		
n = 93	Baseline ¹⁸F-DG-PET/CT positive (n = 21)	Baseline ¹⁸F-DG-PET/CT negative (n=72)
No. of patients undergoing biopsy after baseline ¹⁸ F-DG-PET/CT	12	3
No. of patients with confirmed EM AML in biopsy	10	3
No. of patients with different tumor (other than EM AML) in biopsy	2	0